Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company offers ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver disease related to alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial […]
Read MoreProgenics Pharmaceuticals, Inc. develops medicines and other technologies to target and treat cancer in the United States and internationally. The company’s primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant, recurrent, and/or unresectable pheochromocytoma and paraganglioma; 1404, a […]
Read MoreKalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company’s product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, an intravitreally administered plasma kallikrein inhibitor that is in Phase II […]
Read MoreEvery year, a handful of stocks double over the course of the year. This was even true last year, despite the market having its worst year since the Great Recession, as stocks like Tandem Diabetes (NASDAQ: TNDM), Turtle Beach (NASDAQ: HEAR), Twilio (NASDAQ: TWLO), and Crocs (NASDAQ: CROX) all delivered triple-digit returns. For this year, I’ve got my eye on two stocks […]
Read MoreAntares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company’s injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute […]
Read MoreWe’re heading into earnings season after a particularly difficult fourth quarter that saw the S&P 500 briefly cross into bear market territory on Christmas Eve. Since then, the index has rebounded. However, there’s still quite a bit of ground to make up. In a report from Goldman Sachs, U.S. chief equity strategist David Kostin said […]
Read More